Syndax Pharmaceuticals Inc (SNDX): Operating Cash Flow
-$322.98M
Year ended 2025-12-31
-$220.64M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$322.98M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$274.90M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$160.60M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$133.68M | n/m | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $29.13M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$71.26M | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$50.61M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$68.53M | n/m | 2021-03-12, From 2018-01-01 |
| 2017-12-31 | -$47.37M | n/m | 2020-03-05, From 2017-01-01 |
| 2016-12-31 | -$35.16M | n/m | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | -$2.43M | n/m | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | -$14.39M | n/a | 2017-03-14, From 2014-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | -$322.98M | n/m |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$166.78M | n/m |
| Cryoport, Inc. (CYRX) | 2025-12-31 | -$8.58M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $10.24M | -13.8% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $45.59M | n/m |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | -$57.57M | n/m |
| Liquidia Corp (LQDA) | 2025-12-31 | -$35.69M | n/m |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$115.67M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$27.59M | n/m |
Compare SNDX, PHAT, CYRX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗